Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High <i>CST2</i> Expression and a Favorable Prognosis
Year: 2025
Type: article
Language: en
Topic: Ovarian cancer diagnosis and treatment
Authors and affiliations:
raw_author_name: James Boyle
raw_affiliation_strings: 1Oncology Data Science, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
AstraZeneca (United Kingdom) 1 Cambridge
raw_author_name: Jan Zaucha
raw_affiliation_strings: 1Oncology Data Science, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
AstraZeneca (United Kingdom) 1 Cambridge
raw_author_name: Felicia Ng
raw_affiliation_strings: 1Oncology Data Science, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
AstraZeneca (United Kingdom) 1 Cambridge
raw_author_name: Andreas Spitzmüller
raw_affiliation_strings: 2Computational Pathology GmbH, AstraZeneca, Munich, Germany
AstraZeneca Munich Germany
raw_author_name: Miljenka Vuko
raw_affiliation_strings: 2Computational Pathology GmbH, AstraZeneca, Munich, Germany
AstraZeneca Munich Germany
raw_author_name: Felix J. Segerer
raw_affiliation_strings: 2Computational Pathology GmbH, AstraZeneca, Munich, Germany
AstraZeneca Munich Germany
raw_author_name: Monica Azqueta-Gavaldon
raw_affiliation_strings: 2Computational Pathology GmbH, AstraZeneca, Munich, Germany
AstraZeneca (United Kingdom) 3 Munich, Bavaria
raw_author_name: Marco Testori
raw_affiliation_strings: 2Computational Pathology GmbH, AstraZeneca, Munich, Germany
AstraZeneca Munich Germany
raw_author_name: Amelia Raymond
raw_affiliation_strings: 3Translational Medicine, Oncology R&D, AstraZeneca, Boston, Massachusetts
AstraZeneca (United States) 4
raw_author_name: Barrett R.B. Nuttall
raw_affiliation_strings: 3Translational Medicine, Oncology R&D, AstraZeneca, Boston, Massachusetts
AstraZeneca (United States) 5 Waltham, MA
raw_author_name: Andrea Ennio Storti
raw_affiliation_strings: 4Oncology Data Science Platforms, Oncology R&D, AstraZeneca, Munich, Germany
AstraZeneca Munich Germany
raw_author_name: Sakshi Gulati
raw_affiliation_strings: 5Oncology Data Science Platforms, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
AstraZeneca (United Kingdom) 1 Cambridge
raw_author_name: Shaan Gill
raw_affiliation_strings: 6Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
AstraZeneca (United Kingdom) 1 Cambridge
raw_author_name: Michael Surace
raw_affiliation_strings: 7Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland
AstraZeneca Gaithersburg United States
raw_author_name: Paola Marco-Casanova
raw_affiliation_strings: 6Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
AstraZeneca (United Kingdom) 1 Cambridge
raw_author_name: Emma V. Jones
raw_affiliation_strings: 6Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
AstraZeneca (United Kingdom) 1 Cambridge
raw_author_name: Ben S. Sidders
raw_affiliation_strings: 1Oncology Data Science, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
AstraZeneca Cambridge United Kingdom
raw_author_name: Jorge S. Reis-Filho
raw_affiliation_strings: 8Cancer Biomarker Development, Oncology R&D, AstraZeneca, Gaithersburg, Maryland
AstraZeneca (United States) 4
raw_author_name: Maurizio Scaltriti
raw_affiliation_strings: 7Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland
AstraZeneca (United States) 8 New York, NY
raw_author_name: Anita Semertzidou
raw_affiliation_strings: 6Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
AstraZeneca (United Kingdom) 1 Cambridge
raw_author_name: Helen K. Angell
raw_affiliation_strings: 6Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
AstraZeneca (United Kingdom) 1 Cambridge